AU2021248861A1 - Treating pulmonary inflammatory disease associated with COVID-19 by administering resiniferatoxin - Google Patents

Treating pulmonary inflammatory disease associated with COVID-19 by administering resiniferatoxin Download PDF

Info

Publication number
AU2021248861A1
AU2021248861A1 AU2021248861A AU2021248861A AU2021248861A1 AU 2021248861 A1 AU2021248861 A1 AU 2021248861A1 AU 2021248861 A AU2021248861 A AU 2021248861A AU 2021248861 A AU2021248861 A AU 2021248861A AU 2021248861 A1 AU2021248861 A1 AU 2021248861A1
Authority
AU
Australia
Prior art keywords
composition
rtx
pulmonary
disease
inflammatory disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021248861A
Other languages
English (en)
Inventor
Henry Hongjun Ji
Alexis Nahama
Hanjun Wang
Irving H. ZUCKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
University of Nebraska System
Original Assignee
University of Nebraska Lincoln
Sorrento Therapeutics Inc
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nebraska Lincoln, Sorrento Therapeutics Inc, University of Nebraska System filed Critical University of Nebraska Lincoln
Publication of AU2021248861A1 publication Critical patent/AU2021248861A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2021248861A 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with COVID-19 by administering resiniferatoxin Abandoned AU2021248861A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063002165P 2020-03-30 2020-03-30
US63/002,165 2020-03-30
US202063122858P 2020-12-08 2020-12-08
US63/122,858 2020-12-08
PCT/US2021/022089 WO2021202084A1 (en) 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin

Publications (1)

Publication Number Publication Date
AU2021248861A1 true AU2021248861A1 (en) 2022-10-13

Family

ID=75340289

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021248861A Abandoned AU2021248861A1 (en) 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with COVID-19 by administering resiniferatoxin

Country Status (8)

Country Link
US (1) US20230143545A1 (https=)
EP (1) EP4125871A1 (https=)
JP (2) JP2023519853A (https=)
KR (1) KR20220161423A (https=)
CN (1) CN115666551A (https=)
AU (1) AU2021248861A1 (https=)
CA (1) CA3173611A1 (https=)
WO (1) WO2021202084A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300072A (en) * 2020-08-11 2023-03-01 Sorrento Therapeutics Inc Treatment of pneumonia by nerve ablation
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
GB9826359D0 (en) * 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
CA2880855A1 (en) 2012-08-03 2014-02-06 Mestex Ag Resiniferatoxin solution
EP3131541A4 (en) * 2014-04-14 2018-02-14 Flex Pharma, Inc. Ion channel activators and methods of use
US20200129472A1 (en) * 2017-02-09 2020-04-30 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of peripheral artery disease
MX2020002692A (es) * 2017-09-11 2020-10-14 Sorrento Therapeutics Inc Formulacion de resiniferatoxina.

Also Published As

Publication number Publication date
EP4125871A1 (en) 2023-02-08
CN115666551A (zh) 2023-01-31
CA3173611A1 (en) 2021-10-07
JP2023519853A (ja) 2023-05-15
US20230143545A1 (en) 2023-05-11
WO2021202084A1 (en) 2021-10-07
JP2026042884A (ja) 2026-03-11
KR20220161423A (ko) 2022-12-06

Similar Documents

Publication Publication Date Title
JP2026042884A (ja) レシニフェラトキシンを投与することによるｃｏｖｉｄ－１９と関連する肺炎症性疾患の処置
KR20080103108A (ko) 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법
US20230301700A1 (en) Treating Pulmonary Inflammatory Disease by Neural Ablation
Schaller et al. Trigemino-cardiac reflex during transsphenoidal surgery for pituitary adenomas: methodological description of a prospective skull base study protocol
WO2018113027A1 (zh) 白果内酯作为增效剂在制备防治脑神经损伤性疾病药物的应用
Keegan et al. Pulmonary edema after resection of a fourth ventricle tumor: possible evidence for a medulla-mediated mechanism
KR20060013547A (ko) 확장된 치료 윈도우를 갖는, 반응성 세포, 조직 및 기관의보호, 회복 및 개선을 위한 조직 보호성 사이토카인
KR20100136494A (ko) 아포에쿼린 함유 조성물 및 이의 사용 방법
Yılmaz Anesthesia management for carotid endarterectomy
WALTS et al. The effects of ventilation on the action of tubocurarine and gallamine
Incagnoli et al. Erythropoietin improved initial resuscitation and increased survival after cardiac arrest in rats
Yalcin et al. The effect of centrally administered erythropoietin on cardiovascular and respiratory system of anaesthetized rats
Akcaboy et al. Can ephedrine pretreatment be effective in alleviating rocuronium injection pain?
Kim et al. Effect of low dose ketamine to prevent remifentanil-induced cough: a randomized, double-blind, placebo controlled trial
KR20140015150A (ko) 급성 악화성 천식의 치료 및 이로부터 고통받는 환자의 입원 가능성의 감소
Mohapatra et al. A study of changes in stress factors during elective upper abdominal surgery using different anaesthetic techniques
Moss et al. Effects of 2% enflurane on intracranial pressure and cerebral perfusion pressure
US20240415859A1 (en) Use of isorhoifolin and derivative thereof in promoting nerve repair
RU2766681C1 (ru) Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, для лечения синдрома ишемии-реперфузии у пациентов с ишемическими поражениями органов и конечностей
Bakry et al. The effect of ultrasound guided pecto-intercostal fascial plane block with levobupivacaine on extubation time after on pump coronary artery bypass grafting surgery: A randomised controlled trial
RU2655763C2 (ru) Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
Oliveira et al. Control of pain trough epidural block and incidence of cardiac dysrhythmias in postoperative period of thoracic and major abdominal surgical procedures: a comparative study
Mahendran A Comparative study on three doses of Esmolol to attenuate the Hemo Dynamic Stress Response during Laryngoscopy and Endo Tracheal Intubation
Venkatayogi et al. Intramuscular clonidine versus intramuscular dexmedetomidine to attenuate haemodynamic response to laryngoscopy and intubation: open label randomized trial
Alemanno Complications of Supraclavicular Techniques

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application